Clinical trial
A Multicenter, Open-label Study of Rhopressa® (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
NCT03808688 is registered in ClinicalTrials.gov with Aerie Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-label Study of Rhopressa® (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
- Lead sponsor
- Aerie Pharmaceuticals
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 27, 2018
- Completion date
- July 26, 2019
- Enrollment
- 261 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.